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NICE guidelines -  National Institute for Health and Care Excellence. 
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HTN   - Hypertension 
CAD   - Coronary Artery Disease 
ACS   - Acute Coronary Syndrome 
UTI   - Urinary Tract Infection 
COPD  - Chronic obstructive Pulmonary Disease 
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INTRODUCTION 
PHARMACOECONOMICS  
Pharmacoeconomics is the scientific discipline that evaluates the clinical, economic and 
humanistic aspects of pharmaceutical products, services and programs as well as other health 
care intervention to provide health care decision makers, providers and patients with valuable 
information for optimal outcomes and allocation of health outcomes. 
History: 
    The term Pharmacoeconomics was first time used in public forum was in 1986, at a 
meeting of pharmacists in Toronto, Canada, when Ray Townsend from the Upjohn company, 
used the term in presentation. Ray and few other had been performing studies using the term 
pharmacoeconomics within the pharmaceutical industry since the early eighties today 
pharmacoeconomics research is a flourishing industry with many practitioners, a large research 
and application agenda, several journals and flourishing professional societies including the 
international society for pharmacoeconomics and outcomes research. Why did the term catch on? 
The pharmacoeconomics started with a study of the cost-effectiveness of AZT for the treatment 
of persons with AIDS. 
ECONOMIC BURDEN OF DIABETIS MELLITUS 
 Diabetes Mellitus is one of the leading epidemics globally. Most people are affected by 
this disease. It is associated with high mortality and morbidity rates as well as high economic 
use. The total annual cost for Australians with type 2 diabetes is up to $6 billion including 
healthcare costs, the cost of careers and Commonwealth government subsidies. The average 
annual healthcare cost per person with diabetes is $4,025 if there are no associated 
complications. 
[1] 
 In India according to the study done by Jitendrah Singh the following observation was 
made that the average expenditure per patient per year would be a minimum of INR 4,500 
(approximately US $120). Therefore, the estimated annual cost of diabetes care would be 
approximately 180,000 million INR. 
[2]
The prevalence of diabetes in 2013 in India was only 
slightly higher than the world average (9.1% vs. 8.3% worldwide).
 [3]
 However, due to its very 
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large population, India has the world‘s largest population living with diabetes after China. In 
2013, there were 65.1 million people between 20 and 79 years of age with diabetes and this 
number was predicted to rise to 109 million by 2035. The growing epidemic of type 2 diabetes in 
India has been highlighted in several studies. 
[4]
 
Diabetic Mellitus in rural and urban areas 
A study in Indian patients by Ramachandran et al analyzed the urban-rural expenditure 
on diabetes. The study indicated that the economic burden of diabetes care on families in 
developing countries is rising rapidly, even after accounting for the inflation. The annual family 
income was higher in urban subjects [rupees (Rs) 100,000 or $2,273] than in the rural subjects 
(Rs 36,000 or $818) (P < 0.001). Total median expenditure on health care was Rs 10,000 ($227) 
in urban and Rs 6,260 ($142) in rural (P0.001) subjects.
 [5]
 Another study showed that the lower 
treatment expenditure in rural may be due to issues of less access and affordability rather than 
lower need as assumed and late detection of the disease in these settings often leads to 
catastrophic spending for individuals and households 
[6]
. Socioeconomic differences and the 
urban–rural divide suggest divergence in disease outcomes. In other words, the relatively 
wealthier population living in urban areas spend more on diabetes care and have better outcomes, 
while relatively poorer people living in rural areas tend to have more difficulties accessing 
diabetes care, and therefore spend less on diabetes care and tend to have worse health outcomes 
[7]
 
Out of pocket expenditure  
Out of pocket expenditure refers to patients accessing treatment facilities by spending 
from their own pockets which is a very common practice in India. In developed countries most 
of their health bills are covered b the health insurance companies. Here in India efforts to provide 
health insurance are ongoing and studies have shown that including the private health care up to 
25% that is 300 million people are covered up to 2012. 
[8]
 Therefore the financial burden still 
falls on the individuals since the health insurance is not covering fully. Studies estimate that, for 
a low income Indian family with an adult with diabetes, as much as 20 percent of family income 
may be devoted to diabetes care. For families with a diabetic child, up to 35 percent of income is 
spent on diabetes care. If you have Diabetes for five years you would have spent around Rs 
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1,50,000 on diabetes treatment only. After 10 years you would have spent Rs 4,00,000 and after 
20 years you would have spent Rs 15,00,000. The increase in cost with time is due to the 
increase in complications. 
Therefore Diabetes Mellitus is an expensive disease to treat and it is one of the growing 
pandemic in the world because of the changing lifestyles. Therefore means to cope with the 
disease should be enhanced. Need for getting cost effective means of treating diabetes Mellitus is 
uncompromisable because even though the patients improve on their symptoms, the cost is 
burdening them.  
Diabetes Mellitus 
Definition 
Diabetes Mellitus is a chronic metabolic disease characterized by hyperglycemia which is 
high blood sugar which may be as a result of insulin resistance or reduced insulin production or 
both. Insulin hormone is used to lower the blood sugar preventing the hyperglycemia 
Types 
1. Type 1 Diabetes Mellitus 
 This is also known as insulin dependent diabetes which is as a result of low 
insulin production from the beta cells of the pancreas which is accredited to autoimmune 
destruction. Therefore the blood sugar is not utilized or converted to glycogen thus it 
becomes much in the blood. This type is only treated with Insulin. 
 
2. Type 2 Diabetes Mellitus 
 Also known as insulin independent diabetes mellitus. In this the insulin 
production is present however there is resistance towards the insulin therefore it is not 
utilized and thus the blood sugar becomes relatively high in blood because glucose is not 
utilized by the cells.  
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SYMPTOMS 
 Increased thirst and frequent urination. Excess sugar building up in your bloodstream 
causes fluid to be pulled from the tissues. This may leave you thirsty. As a result, you 
may drink — and urinate — more than usual. 
 Increased hunger. Without enough insulin to move sugar into your cells, your muscles 
and organs become depleted of energy. This triggers intense hunger. 
 Weight loss. Despite eating more than usual to relieve hunger, you may lose weight. 
Without the ability to metabolize glucose, the body uses alternative fuels stored in muscle 
and fat. Calories are lost as excess glucose is released in the urine. 
 Fatigue. If your cells are deprived of sugar, you may become tired and irritable. 
 Blurred vision. If your blood sugar is too high, fluid may be pulled from the lenses of 
your eyes. This may affect your ability to focus. 
 Slow-healing sores or frequent infections. Type 2 diabetes affects your ability to heal 
and resist infections. 
 Areas of darkened skin. Some people with type 2 diabetes have patches of dark, velvety 
skin in the folds and creases of their bodies — usually in the armpits and neck. This 
condition, called acanthosis nigricans, may be a sign of insulin resistance 
 
RISK FACTORS 
 Weight. Being overweight is a primary risk factor for type 2 diabetes. The more fatty 
tissue you have, the more resistant your cells become to insulin. However, you don't have 
to be overweight to develop type 2 diabetes. 
 Fat distribution. If your body stores fat primarily in your abdomen, your risk of type 2 
diabetes is greater than if your body stores fat elsewhere, such as your hips and thighs  
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 Inactivity. The less active you are, the greater your risk of type 2 diabetes. Physical 
activity helps you control your weight, uses up glucose as energy and makes your cells 
more sensitive to insulin. 
 Family history. The risk of type 2 diabetes increases if your parent or sibling has type 2 
diabetes. 
 Race. Although it's unclear why, people of certain races — including blacks, Hispanics, 
American Indians and Asian-Americans — are more likely to develop type 2 diabetes 
than whites are. 
 Age. The risk of type 2 diabetes increases as you get older, especially after age 45. That's 
probably because people tend to exercise less, lose muscle mass and gain weight as they 
age. But type 2 diabetes is also increasing dramatically among children, adolescents and 
younger adults. 
Drugs used to treat diabetes mellitus 
Table 1: Classification of oral antidiabetic drugs 
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COSTS OF TREATING DIABETES MELLITUS 
 Treating Diabetes Mellitus entails both the medical and non medical costs put in 
consideration. Medical costs are those that directly affect the medical aspect of the disease where 
as the non medical costs are those that indirectly affect the treatment of diabetes mellitus they are 
contributing factors. 
Medical Cost 
a. Cost of antidiabetic drug 
b. Cost of laboratory tests  
c. Cost of physicians and nurses  
d. Cost of complications 
e. Cost of hospitalization 
Non Medical costs 
a. Cost of transportation 
b. Work loss days (absenteeism) and low productivity during working days due to 
disease. 
c. Cost experienced by care givers during hospitalization. 
A. Cost of oral antidiabetic drugs 
1. BIGUANIDES 
These are the mostly used first line antidiabetic agents. They are preferred because of their 
benefits. Patients on this drug have lower rates of cardiovascular disease and mortality compared 
to patients on sulphonylureas. Metformin delays progression to diabetes in persons with impaired 
glucose tolerance. It has also been used in treatment of infertility in women with polycystic 
ovarian syndrome. It improves ovulation and menstruation cyclicity and reduces circulating 
androgens and hirsuitis.  
 Studies have also shown that metformin is one of the cost effective therapies in treating 
type 2 diabetes mellitus. Both lifestyle modification and metformin were cost-effective 
interventions for preventing diabetes among high risk-individuals in India and perhaps may be 
useful in other developing countries as well.
 [2] 
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 Other studies showed that when metformin was used in combination with other drugs it 
was cost effective than metformin used singly. A study done in Kenya by Gerald Ochieng 
showed that using combination therapy of Metformin and a DPP4 Inhibitor was more cost 
effective than monotherapy of metformin. 
[10]
Similarly treating DM with combination of 
metformin + glimepride was the most cost effective in another study. 
[11] 
2. SULPHONYL UREAS 
Drugs in this category include glimepride, glicizide and Glibenclamide. These Drugs are 
second line therapy and are used as add ons drugs to Metformin .Adding sulphonylurea to 
metformin targeted both insulin resistance and insulin deficiency.  Sulphonylurea was efficacious 
and cheaper than thiazolidinedione, dipeptidyl peptidase-4 inhibitor, glucagon-like peptide 1 
analogue and insulin. The main side effect of sulphonylurea was hypoglycaemia but there was no 
effect on the body weight when combining with metformin. Fixed dose sulphonylurea/metformin 
was more efficacious at lower dose and reported to have fewer side effects with better adherence. 
Furthermore, fixed dose combination was cheaper than add-on therapy. [
12] 
 
3. MEGLITINIDES
 
Melglitinides are also known as insulin secretagogues. They include repaglinide and 
Nateglinide. These drugs have been seen to be more cost effective than sulfonyl ureas because of 
the sulfonyl ureas side effects e.g. Weight gain and hypoglycemia. The NICE guidelines on Type 
2 Diabetes Mellitus – critical analysis supports the use of Meglitinides as a first line therapy in 
patients who are contraindicated to metformin and as a second line agent to metformin instead of 
sulfonyl ureas as was normal clinical practice. 
[29] 
 
4. ALPHA GLUCOSIDASE INHIBITORS 
Of all available anti-diabetic drugs, α-glucosidase inhibitors seem to be the most effective 
in reducing post-prandial hyperglycemia. They include Acarbose, Voglibose. A study carried out 
by Gussepe et al on alpha Glucosidase inhibitors showed that although the drug acarbose is 
expensive in comparison to other antidiabetic drugs it has good benefits. α-Glucosidase 
inhibitors can be used as a first-line drug in newly diagnosed type 2 diabetes insufficiently 
treated with diet and exercise alone, as well as in combination with all oral anti-diabetics and 
insulin if monotherapy with these drugs fails to achieve the targets for HbA1c and post-prandial 
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blood glucose. As a first-line drug, they are particularly useful in newly diagnosed type 2 
diabetes with excessive PPG, because of their unique mode of action in controlling the release of 
glucose from complex carbohydrates and disaccharides. α-Glucosidase inhibitors may also be 
used in combination with a sulfonylurea, insulin or metformin.
[13] 
 
5. Use of Newer drugs in Diabetes Melitus - DPP4 inhibitors  
These are the newer drugs in the field of diabetes mellitus with less clinical experience. DPP-
4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone 
incretin. Incretins help the body produce more insulin only when it is needed and reduce the 
amount of glucose being produced by the liver when it is not needed. These hormones are 
released throughout the day and levels are increased at meal times. 
 
Medications in the DPP-4 inhibitor family 
Table 2: 
Generic Name Brand or trade name 
Sitagliptin Januvia 
Sitagliptin + Metformin Janumet 
Vildagliptin Galvus 
Vildagliptin + Metformin Eucreas 
Saxagliptin Onglyza 
―For treating elderly T2DM patients, DPP-4 inhibitors were more expensive and less 
effective, i.e. a dominated strategy, than the metformin monotherapy. 
[14]
 ― Another  study on 
cost effectiveneness of DPP4 by Jinsong et al  found that, in patients with type 2 diabetes who 
do not achieve glycemic targets with antidiabetic monotherapy, DPP-4 inhibitors as add-on 
treatment may represent a cost-effective option compared with sulfonylureas and insulin. 
However, high-quality cost-effectiveness analyses that utilize long-term follow-up data and 
have no conflicts of interest are still needed. 
[15] 
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Summary of the antidiabetic drugs 
 It is evident that metformin is the most cost effective drug as compared to all other 
antidiabetics as a montherapy. However more cost effectiveness is achieved when metformin is 
in combination therapy. The most expensive monotherapy is Sitaglpitin as well as less effective.  
 
B. Laboratory Charges.  
The following are the common tests for a diabetic patient which should be done monthly except 
for HBA1c.  However these tests increase due to complications later on. 
a. HBA1c (Glycated Haemoglobin) - This blood test indicates your average blood sugar 
level for the past two to three months. It measures the percentage of blood sugar attached 
to hemoglobin, the oxygen-carrying protein in red blood cells. The higher your blood 
sugar levels, the more hemoglobin you'll have with sugar attached. An A1C level of 6.5 
percent or higher on two separate tests indicates that you have diabetes. An A1C between 
5.7 and 6.4 percent indicates prediabetes. Below 5.7 is considered normal. 
b. Random blood sugar test. A blood sample will be taken at a random time. Regardless of 
when you last ate, a random blood sugar level of 200 milligrams per deciliter (mg/dl) — 
11.1 millimoles per liter (mmol/L) — or higher suggests diabetes. 
c. Fasting blood sugar test. A blood sample will be taken after an overnight fast. A fasting 
blood sugar level less than 100 mg/dL (5.6 mmol/L) is normal. A fasting blood sugar 
level from 100 to 125 mg/dl(5.6 to 6.9 mmol/L) is considered prediabetes. If it's 126 
mg/dL (7 mmol/L) or higher on two separate tests, you have diabetes. 
d. Post parandial blood sugar - A postprandial glucose test is a blood glucose test that 
determines the amount of a type of sugar, called glucose, in the blood after a 
meal. Glucose comes from carbohydrate foods. It is the main source of energy used by 
the body. Normally, blood glucose levels increase slightly after eating. 
Postprandial‖ sugars taken two hours after meals should be less than 140 mg/dl 
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Summary of laboratory charges of diabetes 
Laboratory charges are part of medical costs incurred by patients. Studies show that the 
laboratory charges take up to 10% - 40% of total medical costs incurred by patients and cannot 
be avoided since patients need to monitor their sugar levels every once and again. 
 
C. Physician Charges  
These are the charges that patients pay in order to see a physician. These charges have been 
seen to consume at least 5 – 25 % of the total medical costs incurred by the patient. [11]These 
charges are varied from hospital to hospital and are inevitable unless in government hospitals in 
specific countries 
D. Cost of complications 
 Diabetes Mellitus is a disease with numerous complications which when not treated will 
lead to death or reduced health in patients. Therefore along treatment of DM, the patients are 
faced with the task of treating the complications. This makes DM an expensive disease to treat.  
DM direct treatment costs increased with the presence and progression of chronic DM related 
complications. 
[16] 
The following are the complications of dm 
 Heart and blood vessel disease. Diabetes dramatically increases the risk of various 
cardiovascular problems, including coronary artery disease with chest pain (angina), heart 
attack, stroke, narrowing of arteries (atherosclerosis) and high blood pressure. 
 Nerve damage (neuropathy). Excess sugar can injure the walls of the tiny blood vessels 
(capillaries) that nourish your nerves, especially in the legs. This can cause tingling, 
numbness, burning or pain that usually begins at the tips of the toes or fingers and 
gradually spreads upward. Poorly controlled blood sugar can eventually cause you to lose 
all sense of feeling in the affected limbs. Damage to the nerves that control digestion can 
cause problems with nausea, vomiting, diarrhea or constipation. For men, erectile 
dysfunction may be an issue. 
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 Kidney damage (nephropathy). The kidneys contain millions of tiny blood vessel clusters 
that filter waste from your blood. Diabetes can damage this delicate filtering system. 
Severe damage can lead to kidney failure or irreversible end-stage kidney disease, which 
often eventually requires dialysis or a kidney transplant. 
 Eye damage. Diabetes can damage the blood vessels of the retina (diabetic retinopathy), 
potentially leading to blindness. Diabetes also increases the risk of other serious vision 
conditions, such as cataracts and glaucoma. 
 Foot damage. Nerve damage in the feet or poor blood flow to the feet increases the risk of 
various foot complications. Left untreated, cuts and blisters can become serious infections, 
which may heal poorly. Severe damage might require toe, foot or leg amputation. 
 Hearing impairment. Hearing problems are more common in people with diabetes. 
 Skin conditions. Diabetes may leave you more susceptible to skin problems, including 
bacterial and fungal infections. 
Summary of treating diabetic complications 
 On an average, diabetic patients with foot complications (19020 INR) and those who 
have presence of two complications (17633 INR) spent 4 times more and patients with chronic 
kidney disease (12690 INR), cardiovascular complications (13135 INR) and retinal 
complications (13922 INR) spent three times more than patients without any complications 
(4493 INR). The total median expenditure for the hospital admissions in the previous 2 years was 
significantly higher for patients with foot complications (150000 INR) and cardiovascular 
complications (200000 INR) and it was highest if they have presence of two complications 
(282500 INR) 
[17] 
NEED   
 The demand for and the cost of health care are increasing in all countries as the 
improvement in and sophistication of health technologies. Cost of medicines are growing 
constantly as new medicines are marketed and are under patent law, preference of drug therapy 
over invasive therapy, discovering various off label uses of existing drugs and the irrational drug 
prescription.  
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Therefore the following are the need of pharmacoeconomic study: 
1)  Rising health expenditures have led to the necessity to find the optimal therapy at the 
lowest price 
2) Numerous drug alternatives and empowered consumers also fuel the need for economic 
evaluations of pharmaceutical products 
3) The increasing cost of healthcare products and services has become a great concern for 
patients, healthcare professionals, insurers, politicians and the public.  
4) Healthcare resources are not easily accessible and affordable to many patients; therefore 
pharmacoeconomic evaluations play an important role in the allocation of these 
resources. 
5)  For the formulating of the formulary the pharmacoecomic knowledge is necessary for 
the pharmacist and physicians. 
6) It is increasingly becoming important for health policy decision making. Its need is 
undeniable, especially in developing countries. 
 Pharmacoeconomics is an innovative method that aims to decrease health 
expenditures, whilst optimizing healthcare results. 
 
METHODS OF PHARMACOECONOMICS 
There are basically 4 categories or types of pharmacoeconomic studies. These are 
presented here in order of detail,  
 1. Cost-minimization analysis (CMA) 
  2. Cost-effectiveness analysis (CEA)  
 3. Cost-utility analysis (CUA)  
 4. Cost-benefit analysis (CBA)  
1. COST MINIMIZATION ANALYSIS 
 This involves measuring only costs, usually only to the health service, and is 
applicable only where the outcomes are identical and need not be considered separately. 
An example would be prescribing a generic preparation instead of the brand leader (lower 
cost but same health outcomes). 
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2. COST EFFECTIVE ANALYSIS 
Compares the cost of drugs and their benefits and the benefits are measured in terms of 
natural units e.g.( ulcers healed ,FBS reduced ) and the cost is measured in terms of money. CEA 
is the most commonly applied form of economic analysis in the literature, and especially in drug 
therapy. It does not allow comparisons to be made between two totally different areas of 
medicine with different outcome. E.g. comparing cost and effectiveness of antidiabetics whose 
both effect is reduction of FBS. 
 
3. COST UTILITY ANALYSIS 
This is similar to cost effectiveness in that the costs are measured in money and there is a 
defined outcome. But here the outcome is a unit of utility (e.g. a QALY). Since this endpoint is 
not directly dependent on the disease state, CUA can in theory look at more than one area of 
medicine, e.g. cost per QALY of coronary artery bypass grafting versus cost per QALY for 
erythropoietin in renal disease. 
 
4. COST BENEFIT ANALYSIS  
Here, the benefit is measured as the associated economic benefit of an intervention (e.g. 
monetary value of returning a worker to employment earlier), and hence both costs and benefits 
are expressed in money. CBA may ignore many intangible but very important benefits not 
measurable in money terms, e.g. relief of anxiety. CBA may also seem to discriminate against 
those in whom a return to productive employment is unlikely, e.g. the elderly, or the 
unemployed.  
E.g.  Comparing cost and effectiveness of antidiabetics whose both effect is reduction of FBS. 
 
COST EFFECTIVENESS STUDY 
Cost-effectiveness analysis (CEA) is a form of economic analysis that compares the 
relative costs and outcomes (effects) of different courses of action. Cost-effectiveness analysis is 
distinct from cost–benefit analysis, which assigns a monetary value to the measure of effect. It is 
used to compare different drugs which have the same outcome. The cost and effectiveness of the 
drugs are compared and the cost effective drug is considered. 
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CEA is most useful when analysts face constraints which prevent them from conducting 
cost-benefit analysis. The most common constraint is the inability of analysts to monetize 
benefits. CEA is commonly used in healthcare, for example, where it is difficult to put a value on 
outcomes, but where outcomes themselves can be counted and compared, e.g. ‗the number of 
lives saved‘ 
 
CEA measures costs in a common monetary value (££) and the effectiveness of an option 
in terms of physical units. Because the two are incommensurable, they cannot be added or 
subtracted to obtain a single criterion measure. One can only compute the ratio of costs to 
effectiveness in the following ways: 
    CE ratio = C1/E1  
    EC ratio = E1/C1 
Where: C1 = the cost of option 1 (in £); and E1 = the effectiveness of option 1 (in physical 
units).  
ICER 
The incremental cost-effectiveness ratio (ICER) is a statistic used in cost-effectiveness 
analysis to summarize the cost-effectiveness of a health care intervention. It is defined by the 
difference in cost between two possible interventions, divided by the difference in their effect. 
ACER 
The average cost-effectiveness ratio (ACER) is the ratio of the cost to benefit of an 
intervention without reference to a comparator. 
 Result of cost effectiveness analysis is expressed as an average cost effectiveness ratio 
(ACER) or as incremental cost effectiveness ratio (ICER). 
          ACER/ICER = healthcare cost divided by clinical outcome /benefit. 
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LITERATURE REVIEW 
 Ping et al in a study of economic impact of diabetes 2010 surveyed that Global health 
expenditures to prevent and treat diabetes and its complications will total at least US dollar 
(USD) 376 billion in 2010. By 2030, this number will exceed some USD 490 billion. 
Expressed in International Dollars (ID), which correct for differences in purchasing power, 
the global expenditures on diabetes will be at least ID418 billion in 2010, and at least ID561 
billion in 2030. An average of USD703 (ID878) per person will be spent on diabetes in 2010 
globally. Expenditures spent on diabetes care are not evenly distributed across age and 
gender groups. More than three-quarters of the global expenditure in 2010 will be used for 
persons who are between 50 and 80 years of age. Also, more money is expected to be spent 
on diabetes care for women than for men.
[18]
 
 
  American diabetes association 2016 in the staggering costs of diabetes mellitus in 
America had the following alarming findings that in Americans having  diabetes $1 in $3 
Medicare dollars is spent caring for people with DM. Diabetes and prediabetes cost in 
America $322 billion. 86 million Americans have prediabetes and 1$ in 5$ health care 
dollars is spent caring for people with diabetes. Today 3,835 Americans will be diagnosed 
with DM. today diabetes will cause 200 Americans to undergo an amputation, 136 to enter 
end stage kidney disease treatment and 1,795 to develop severe retinopathy that can lead to 
severe blindness. This is quite already very alarming and shows that something has to be 
done. 
 
  Jitendrah Singh, Economic burden of diabetes mellitus found that The average 
expenditure per patient per year would be a minimum of INR 4,500 (approximately US 
$120). Therefore, the estimated annual cost of diabetes care would be approximately 180,000 
million rupees.
5
 In India, estimates suggest that 85–95% of all health care costs are borne by 
individuals and their families from household income. The lowest income groups bear the 
greatest burden, paying a larger proportion of household income toward diabetes care. Direct 
expenses consume 27–34% of household incomes of rural and urban poor people while the 
middle-to-high income groups in rural and urban areas consume 5.0–12.6% and 4.8–16.9% 
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of income respectively on diabetes care. Year-on-year increases in this proportion are greater 
in impoverished groups, worsening with duration of diabetes, presence of complications, 
hospitalization, surgical therapy and glycemic control requiring insulin .
[2]
 
 
  Ahmad et al, comparing knowledge of DM among rural and urban diabetics 2007 
discovered that urban diabetic patients are more aware than rural diabetic patients about 
diabetes mellitus. Therefore the rural patients have an increased morbidity and mortality rate 
compared to urban patients due to lack of disease knowledge.
[20]
 
 
 David C Klonoff in the study the increasing incidence of Diabetes Mellitus in 21st 
century determined the reason for the uprising pandemic is due to increased obesity in the 
USA. He said as many obesity cases were rising also diabetic cases were                          
increasing. This he said could be due to increasing intake of fast foods.
[21]
  
 
 Sujatha sought to find out why India has a rise in the chronic disease in her study 
Prevalence of DM 2015 in India and she came up with the following reasons : Genetic 
factors are among the greatest contributors to the rapid spread of this disease. On an average, 
Indians are four times more likely to develop diabetes than Europeans, based solely on 
genetic outlook. Cultural and social factors are no less important. The Indian diet is rich in 
carbohydrates and saturated fats. A typical Indian diet is has more calories and sugar than 
required by the body. This is the cause of obesity, which in turn leads to diabetes. Urban 
migration and change in lifestyle is another factor that must be considered in the study of 
diabetes in India. The younger generations are increasingly choosing a sedentary lifestyle. 
With rising standard of living comes the tendency to consume processed sugary foods. 
[22]
 
 
  Giwa A et al on cost effectiveness analysis of antidiabetic therapy sought to find out the 
cost effective therapies being utilized in the hospital and they came up with the following 
that Glibenclamide was the most cost effective monotherapy and Glibenclamide and 
metformin were the most cost effective combined therapy.
[23]
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   D Limaye et al  on a cost effectiveness study of antidiabetic drugs in Mumbai studied 
the prescription pattern and found out that Glimepride and metformin were the most cost 
effective followed by metformin.
[24]
 
 
 Abdelaziz MSL et al on Pharmacoeconomic evaluation agents in Bangalore did a cost 
effective analysis and a cost of illness study on diabetes mellitus treatment. They found out 
that treating DM is expensive and most patients paid 3000-8000 INR in treating DM during 
period of study and on the most cost effective drugs they found that the combination of 
metformin and Glimepride was the most cost effective combination.
[11]
 
 
 Ghalamreza Y. et al on prescription pattern study in T2DM in outpatients in Iran 
studied the prescription pattern of DM and found out the following Out of the 1118 
prescriptions of antidiabetic drugs studied, 424 (37.9%) were for women and 694(62.1%) 
were for men with mean age of 56.2±11 years. Oral antidiabetic drugs were prescribed for 
777(69.5%) and 30.5% of patients received insulin. Biguanides were the most frequently 
prescribed drugs (61.7%) followed by sulfonylurea (59.9%), alpha-glucosidase inhibitors 
(4.5%), repaglinide (NovoNorm®) (2.7%) and thiazolidinediones (1.7%). Metformin 690 
(61.7%) and glibenclamide 670 (59.9%) were the most frequently prescribed antidiabetic 
drug. In comparison between the monotherapy and combination they found out that About 
46.9% of patients received monotherapy and a total of 594 (53.1%) patients were on 
combination therapy of 2 or more antidiabetic drugs. The Combination of glibenclamide plus 
metformin (41.5%) was the most commonly prescribed antidiabetic drug combination in 
diabetic outpatients. Most common prescribed drugs associated with DM were found to be 
antihypertensive/antianginal (65%) and lipid lowering drugs (33.3%). 
[25]
 
 
 Nasir T et al in a study on medication adherence in DM and self management practices 
in Ethiopia observed the diabetic patients and their medication adherence. He found out that 
Majority of the patients with type 2 diabetes in Ethiopia are managed by OHA monotherapy 
mainly glybenclamide and metformin. While the current prescribing strategy do not achieve 
glycemic control on majority of the patient. This is due to poor adherence with the prescribed 
drug regimen and poor knowledge and practice of successful self management.  Therefore he 
attributed the lack of achieving glycemic control to medical non adherence. 
[26]
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 Ranjit U et al on a study on DM and its complications in India did an elaborate study on 
the main complications diabetic patients had. He discovered that the increase of 
complications was the more cause of morbidity and mortality. Among the complications 
discussed he found out that more than 65% of patients with T2DM die of cardiovascular 
disease; of these, nearly 80% are attributable to coronary artery disease (CAD). The 
susceptibility of Asian Indian individuals to CAD is well known. Compared with white 
individuals, CAD tends to develop a decade or two earlier and triple vessel diseases is more 
common; mortality after an acute coronary event is also 40% higher in Asian Indian patients. 
The presence of T2DM seems to confer a 3–4 times higher risk of cardiovascular disease to 
Asian Indian individuals than to their white counterparts, even after adjusting for sex, age, 
smoking status, hypertension and obesity. He also had a finding on diabetic foot ulcer that 
Diabetic foot ulcers and infections are responsible for >30% of the hospitalizations related to 
diabetes mellitus. 25% of people with diabetes mellitus are estimated to develop a foot ulcer 
during their lifetime. Diabetic foot ulceration is also an expensive complication of diabetes 
mellitus, owing to both medical care and on account of time lost from work and loss of 
income and financial independence.
[27]
 
 
 Amandeep S et al in a study of drug utilization and pharmacoeconomics of antidiabetic 
drugs found out the most cost effective antidiabetic drug utilized and they found out that 
Metformin was the most common OAD agent and insulin asparte was the most common 
injectable anti-diabetic drug prescribed in patients withT2DM. The newer anti-diabetic drugs 
sitagliptin and newer insulin analogues were also prescribed to a great extent. Overall, the 
prescribing trend was rational to a great extent and had improved since the earlier study in 
the same institute. The most cost-effective anti-diabetic therapy was combination therapy of 
glipizide and metformin.
[28]
 
 
 Gerald Ochieng in a study done in Kenya about comparative cost effectiveness of 
metformin therapy and metformin and DPP4 combination therapy discussed elaborately 
that the use of the newer drugs DPP4 in a  combination with metformin was quite cost 
effective as compared to using metformin as a single therapy. 
[10]
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  Pheil L et al in a study on what next after metformin? Focused on the use of sulphonyl 
ureas. Adding sulphonylurea to metformin targeted both insulin resistance and insulin 
deficiency. Sulphonylurea was efficacious and cheaper than thiazolidinedione, dipeptidyl 
peptidase-4 inhibitor, glucagon-like peptide 1 analogue and insulin. The main side effect of 
sulphonylurea was hypoglycaemia but there was no effect on the body weight when 
combining with metformin. Fixed dose sulphonylurea/metformin was more efficacious at 
lower dose and reported to have fewer side effects with better adherence. Furthermore, fixed 
dose combination was cheaper than add-on therapy. In conclusion, sulphonylurea was 
feasible as the second line agent after metformin as the combination targeted on two 
pathways, efficacious, cost-effective and had long safety history. Fixed dose combination 
tablet could improve patient‘s adherence and offered an inexpensive and more efficacious 
option regardless of original or generic product as compared to add-on therapy. 
[12]
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AIM AND OBJECTIVES 
AIM  
 To determine the pharmacoeconomic burden and the oral cost effective therapy in the 
management of Type 2 Diabetes Mellitus  
OBJECTIVES 
- To document the prescription given to the patients. 
- To assess the cost of oral anti diabetic drugs. 
- To evaluate the effectiveness of the prescribed drugs. 
- To determine the cost effectiveness of the oral hypoglycemic agents given. 
- To calculate the direct medical costs incurred by the ambulatory diabetic patients in one 
month. 
- To come up with the total cost of illness incurred by all the patients in one month. 
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METHODOLOGY 
Study design:-  
 Retrospective – Pharmacoeconomic study- cost effective analysis 
Study site:-  
 This retrospective – cost effective study was carried at the teaching hospital of PSG 
Medical Sciences and Research Institute, Coimbatore. This is a multispecialty 1000 bedded 
tertiary care hospital located in south region of Tamilnadu. 
Study population: 
 Patients files from January to June 2016 who have Type 2 diabetes mellitus and are 
taking oral antidiabetic drugs. 
Population size: 
 210 patients who suited the inclusion criteria were selected for the study. 
Study period:  
 Study was carried out for the period of 6 months from October 2016 to March 2017. 
Study Approval:  
 The protocol of the study was submitted to the Institutional Human Ethics Committee of 
our study hospital. The study was approved with the proposal number of 16/340 by the 
committee. 
Data source: 
 Patients files from the Medical Record Department. 
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Patients Selection:  
Inclusion Criteria –  
 Age: any age 
 Gender: male and female 
 Patients with type 2 DM 
 Patients on oral hypoglycemic drugs 
 Patients who came back for review 
Exclusion criteria: 
 Type 1 DM 
 Patients with type 2 DM but are on insulin 
 Patients who are severely ill 
 Pregnant and lactating patients 
STUDY PROCEDURE: 
 Study was selected after much analysis of the diseases and the decision was made after 
much consideration. 
 
 In conjunction with my guide, I have selected the study on Pharmacoeconomic evaluation 
of oral antidiabetic and before proposing the study to ethical committee, I have done 
preliminary literature survey to design the data collection form. 
 
 The study protocol was prepared and submitted in advance to the Institutional Human 
Ethics Committee (IHEC) for approval. The protocol was approved by the IHEC in the 
month of October 2016. This was then intimated to the Professors, Head of department of 
laboratory and Medical record department. 
 
 The study was commenced on the month of October 2016, in the MRD of PS G 
Hospitals, Coimbatore. The patients files were studied carefully and the data collected in 
the data collection form. 
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 The collected files were screened for their demographic profiles which included the 
patients‘ age, sex, complications, laboratory investigations, drugs prescribed and the 
charges of the laboratory, physician charges and the complication charges. 
 
 The charges of the laboratory investigations were acquired from the microbiology and 
pathology departments and the cost of drugs were acquired from HIS and the charges of 
physician were acquired from the patients‘ files. 
 
 The effect of the drugs was determined by calculation the p value of both the 
monotherapy and combination therapy using FBS as the unit of comparison. 
 Later the cost effective therapy was determined by calculating the ICER and ACER and 
the cost effective monotherapy and combination therapy was determined. 
 
 The total cost of illness was determined by totaling the charge incurred by the drugs, 
laboratory investigations, the physician charges and the charges of the complication. 
 
Outcome Measure: Incremental Cost Effective Ratio (ICER) 
ICER = (Cost of X – Cost of Y)/ ( Effect of X – Effect of Y) 
 
Data Interpretation: ICER Quadrant plane 
 
 
 II Quadrant  I Quadrant 
 (ICER ≤ 0)  ICER ≥ 0 
  
 
 III Quadrant  IV Quadrant 
 ICER ≥ 0  ICER≤ 0 
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Data Report: ICER Decision Matrix 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low cost 
 High Effect 
  Low cost 
 Low Effect 
High cost 
Low effect 
High Cost 
High Effect 
Cost                      Dominant 
 Effective           
 
 
 
Excluded            Questionable 
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FLOW CHART 
Patient‘s files 
↓  
Selected patients 
↓  
Patients demographic details collected 
↓ 
Drugs prescribed and their costs collected 
↓  
Cost Effective therapies established 
↓ 
Cost of complication, lab, physician and drugs charges collected 
↓ 
Cost of illness calculated. 
↓ 
Discussion and Conclusion 
exclusion/inclusion criteria 
data collection forms 
ICER and ACER calculation 
summation of total costs 
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RESULTS 
Table No 3: Age wise distribution of Diabetic patients 
Age in years No of patients(n=210) Percentage 
30-40 11 5.2% 
40-50 11 5.2% 
50-60 62 29.5% 
60-70 90 42.85% 
70-80 34 16.19% 
80-90 2 0.95% 
 
 
Figure No 1: Age wise distribution of diabetic patients 
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Table 4: Gender wise distribution 
GENDER No of patients (n=210) Percentage 
Male 126 60 
Female 84 40 
 
 
Figure 2: Gender wise distribution 
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Table No 5: Co-morbidities of Diabetes Mellitus 
Co- morbidities No of patients (n=210) Percentage 
SHT 100 47% 
FOOT ULCER 33 15% 
DLP 24 11.4% 
ACS 20 9.5% 
UTI 11 5.2% 
COPD 15 7.14% 
OTHERS 7 3.33% 
 
 
Figure No 3: Co-morbidities of Diabetes Mellitus 
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Table No 6: Social History of Diabetic Mellitus Patients 
Social History No of patients (n=210) Percentage 
Alcoholic 91 43% 
Non alcoholic 119 57% 
Smoker 88 41.9% 
Non smokers 122 58.09% 
Both alcoholic and smokers 60 28.57% 
 
 
Figure No 4: Social History of DM patients 
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Table No 7:  Classification of oral antidiabetic drugs. (Monotherapy) 
Class of drugs No of patients Percentage 
Biguanides 47 22% 
Sulphonyl ureas 23 10.9% 
Meglitinides 5 2.38% 
Alpha glucosidase inhibitors 2 0.95% 
Thiazolinediones 0 0% 
DPP4 inhibitors 5 2.38% 
 
Figure No 5: Classification of oral antidiabetic therapy (monotherapy) 
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Table No 8: Percentage of oral antidiabetics drugs (monotherapy) 
Brand Name Generic Name No of patients 
taking 
Percentage of 
patients 
Glycomet Metformin 47 22.3% 
Glycinorm Glicazide 18 8.57% 
Gluconorm Repaglinide 5 2.38% 
Amaryl Glimepride 5 2.38% 
 
 
Figure No 6: Percentage of oral antidiabetic drugs (monotherapy) 
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Table No 9: percentage of oral antidiabetic drugs (combination therapy) 
a. Combinations with biguanides and sulphonyl ureas 
Drugs names No of patients Percentage 
Gemer ( Glimepride + metformin) 3 1.42% 
Glycomet + Gemer ( Glimepride + metformin) 4 1.89% 
Glycomet +Dianorm ( metformin + Glicizide) 10 4.74% 
Glyciphage + semiglynase ( Glipizide) 5 2.37% 
Glimisave + Glycomet 6 2.8% 
Glycomet + Reclimet ( metformin + Glicizide) 3 1.42% 
Glipizide + metformin 9 4.27% 
Glycomet +glimepride  11 5.22% 
Glycomet + glycinorm 8 3.79% 
Total  59 28.09% 
b. Combinations of sulphonyl ureas and DPP4 inhibitors 
 
Drug names No of patients percentage 
Glycinorm + Galvus (vidagliptin) 3 1.36% 
Glimepride + sitagliptin 15 6.81% 
Glycinorm +galvusmet 4 1.82% 
Total  22 10.38% 
 
C. Combination of biguanides and DPP4 inhibitors. 
 
Drug names No of patients Percentage 
Janumet (metformin + sitagliptin) 2 0.568% 
Galvusmet (Vidagliptin+metformin)   1 0.24% 
Galvus ( vidagliptin) + Glycomet 3 0.85% 
Total 6 1.42% 
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d. Combination of three drugs 
Drug names No of patients Percentage 
Gemer( Glimepride + metformin) + Gluconorm 
( repaglanide) 
9 4.28% 
Glucobay ( acarbose) + Glicizide + Janumet 
(sitagliptin +metformin) 
3 1.42% 
Reclimet ( metformin + Glicizide)+ istamet  
(janumet ) 
4 1.90% 
Janumet ( siatgliptin + metformin ) + 
Glimepride  
6 2.85% 
Total  22 10.47% 
 
e. Combination of alpha glucosidase inhibitors and other drugs 
 
Drug names No of patients Percentage 
Glycomet + Glucobay (acarbose) 7 3.33% 
Gemer + Glucobay 4 1.90% 
Glicizid + volgbose 6 2.86% 
Glycinorm + Glucobay 6 2.86% 
Total 23 10.95% 
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Table No 10: percentage of combined oral antidiabetic therapy between classes 
Class of drugs No of patients Percentage 
Biguanide + sulphonyl ureas 59 28.09% 
Sulphonyl ureas + DPP4 inhibtors 22 10.38% 
biguanides + DPP4 inhibitors 3 1.425 
alpha glucosidase inhibitors + others 22 10.95% 
Combination of three drugs 23 10.74% 
 
Figure No 7: percentage of combined oral antidiabetic therapy (classes) 
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Table No 11: Management of complications of type 2 DM 
Name of 
complication 
Names of drugs given No of patients Percentage of 
patients 
SHT  
N=100 
T cardace ( Ramipril) 
T Telma ( Telmasartan) 
T amlodipine  
T Repace (lorsatan) 
T Lasix (furosemide) 
T Hipril (lisinopril) 
T Doxasazin  
28 
19 
10 
15 
10 
15 
3 
28% 
19% 
10% 
15% 
10% 
15% 
3% 
Foot ulcer  
 
N= 33 
Pregablin 
Neurobion forte 
Ultracet 
T Dalacin (clindamycin)  
25 
10 
15 
30 
75% 
30% 
45% 
90% 
Dyslipedemia 
N= 24 
T Aztor (artovastatin) 
T Rosuvas (Rosuvastatin) 
14 
6 
70% 
30% 
ACS 
N= 20 
T ecosprin 
T Storvas 
T Clopilet 
20 
14 
20 
100% 
70% 
100% 
UTI  
N= 11 
T Levoflox 
T Nitofurantoin 
4 
7 
57% 
63.6% 
COPD 
N=15 
T Montek LC 
Doxophylline 
C .Mucinac 
7 
11 
3 
46% 
73.3% 
20% 
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Figure No 8: Management of SHT in Diabetic patients 
 
 
Figure no 9: Management of diabetic Foot ulcer 
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Figure No 10: Management of Dyslipedemia 
 
 
 
FIGURE NO 11: Management of acute coronary syndrome 
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Table No 12: cost of oral antidiabetic drugs 
Name of drug Cost of single drug in Rs Cost of drug in a month 
Metformin 0.89 90 
Glimepride 3.15 189 
Glycinorm 2.66 160.73 
Gluconorm 2.8 168 
Janumet 12.63 758 
Gemer 4.80 328 
Amaryl  6.08 365 
Galvusmet 3.58 215 
Gemer + glycomet 6.30 372 
Glycomet + dianorm 4.63 300 
Glycinorm + Galvus 25.47 780 
Glyciphage + semiglynase 10.20 208 
Glimisave + glycomet 4.78 210 
Galvus + Glycomet  22.08 1397 
Gemer + Gluconorm 7.92 356 
Glycomet + Reclimet 8.12 285 
Glipizide + Metformin 4.78 1225 
Glimipride + Sitagliptin 25.47 408 
Glycomet + Glimepride 3.98 406 
Glucobay+ Glicizide+ Janumet 293.27 737 
Glycomet + Glucobay 9.24 279 
Gemer + Glucobay 11.67 936 
Glicizid + Volix 9.99 800 
Reclimet + Istamet 348.53 892 
Glycinorm + Galvusmet 214.84 825 
Glycinorm + Glucobay 12.05 342 
Janumet + Glycinorm 288.82 1490 
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Table No 13: Cost and FBS reduction of oral antidiabetics (monotherapy) 
 Cost of single drug Cost per month Avg FBS reduced 
Metformin 1.5 90 42.03mg/dl 
Glicizide 3.15 160.73 22.26mg/dl 
Repaglanide 2.26 168 7.33mg/dl 
Glimepride 6.08 365 19.00mg/dl 
 
 
Figure No 12: cost and FBS reduction of oral antidiabetics (monotherapy) per month 
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Table No 14: Cost and FBS reduction of oral antidiabetic drugs (combination therapy) 
Category  Generic name  Cost in one month AVG FBS reduction 
1. Glimepride + 
metformin 
a. Gemer 
 
b. Glycomet + 
Gemer 
 
c. Glycomet + 
Glimepride 
328 
 
372 
 
 
406 
36 mg/dl 
 
56.50 mg/dl 
 
 
47.90 mg/dl 
2. Glicizide + 
metformin 
a. Glycomet+ 
Dianorm 
 
b. Glimisave + 
Metformin 
 
c. Glycipahge + 
semiglnase 
 
d. Glycomet + 
Reclimet 
 
e. Glycomet + 
Glycinorm 
300 
 
 
210 
 
 
208 
 
 
285 
 
 
270 
18.30 mg/dl 
 
 
44.83 mg/dl 
 
 
19.60 mg/dl 
 
 
36.66 mg/dl 
 
 
80.37 mg/dl 
 
Figure No 13: Cost and FBS reduction of oral hypoglcemic drugs  
(biguanide and sulphonyl ureas) 
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Table No 15: cost and FBS reduction of oral hypoglycemic drugs (DPP4 combinations) 
category Brand name Generic name Cost in 
a month 
Avg FBS 
reduced 
Mg/dl 
Dpp4 with 
biguanides 
a. Janumet 
 
 
b. Galvusmet 
 
 
c. Galvus + Glcomet 
a. sitagliptin 
+metformin 
 
b. vidagliptin+ 
metformin 
 
c. vidalgliptin + 
Metformin 
 
d. average 
758 
 
 
215 
 
210 
 
 
394.3 
32 
 
 
56.50 
 
39.66 
 
 
42.72mg/dl 
DPP4  
with 
sulphonyl 
ureas 
a. Glycinorm+ Glavus 
b. Glimepride+sitagliptin 
c. Glycoemt + Galvus 
Glicizide+ vidagliptin 
Glimepride + sitagliptin 
Glicizde + Vidagliptin 
 average 
780 
408 
825 
671 
25.66 
12.60 
67.50 
35.25 
mg/dl 
 
Figure No 14: cost and FBS reduction of oral antidiabetic drugs ( DPP4 combinations) 
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Table No 16: cost and FBs reduction of oral antidiabetics  
(alpha glucosidase inhibitors combinations) 
Brand name Generic name Cost per month AVG FBS reduction 
Glycomet+ Glucobay Metformin + 
Acarbose 
279 78mg/dl 
Gemer + Glucobay Glimepride 
+metformin + 
acarbose 
936 75.50mg/dl 
Glicizide + voligbose Glicizide + voglibose 800 65.16mg/dl 
Glycinorm + 
Glucobay 
Glicizide + Acarbose 342 89.50mg/dl 
 
Figure No 15: cost and FBS reduction of oral antidiabetic drugs (alpha glucosidase 
inhibitors combinations) 
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Table No 17:  classification of lab investigations for diabetic patients 
 
Name of lab 
investigation 
Price of lab 
investigation 
No of patients n=210 Percentage of 
patients 
FBS 80 210 100% 
RBS 80 102 48% 
PPBS 80 177 84.2% 
HBA1c 600 120 57.14% 
 
Figure No 16: classification of lab investigations for diabetic patients 
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Table No 18: Effectiveness of oral antidiabetic drugs  
Brand name Generic name FBS 
before 
therapy 
FBS after 
therapy 
Mean FBS 
reduction 
(mg/dl) 
P value 
(before 
and after 
FBS) 
Monotherapy       
Glycomet  Metformin  185.87 140.71 42.03 0.001** 
Glycinorm Glicizide 155.8 140.30 22.26 0.015 
Gluconorm Repaglanide 114 106.6 7.33 0.303 
Amaryl  Glimepride  126.33 107.33 19.00 0.228 
Combianation  Therapy      
Gemer  Glimepride + metformin 187 157 36.00 0.113 
Glycomet + 
Gemer  
Glimepride + metformin 199 142.5 56.50 0.058 
Glycomet 
+Dianorm 
Metformin  + Glicizide 102 97 18.30 0.001** 
Glyciphage + 
semiglynase 
Metformin+ Glipizide 131 111.4 19.60 0.001** 
Glimisave + 
Glycomet 
Glimepride + 
Metformin 
157.8 113 44.83 0.000*** 
Glycomet + 
Reclimet  
Metformin + glicizide 224.67 188 36.66 0.053 
Glipizide + 
metformin 
Glipizide + metformin 133.89 116.33 17.55 0.000*** 
Glycomet 
+glimepride 
Metformin + glimepride 220.63 172.92 47.90 0.000*** 
Glycomet + 
glycinorm 
Metformin +glicizide 188 107 80.37 0.000*** 
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Brand name Generic name FBS 
before 
therapy 
FBS after 
therapy 
Mean FBS 
reduction 
(mg/dl) 
P value 
(before 
and after 
FBS) 
DPP4 
combinations 
     
Glycinorm + 
Galvus  
Glicizide + vidagliptin 143 123 25.66 0.000*** 
Glimepride + 
sitagliptin 
Glimepride +sitagliptin 116 103.4 12.60 0.012* 
Glycinorm 
+galvusmet 
Glicizide + Vidagliptin 
+ Metformin 
267 196 67.50 0.000*** 
Janumet Metformin +sitagliptin 171 139 32.00 0.458 
Galvusmet Vidagliptin + 
Metformin 
88 73 56.50 Not 
possible 
Galvus  + 
Glycomet 
Vidagliptin+ 
Metformin 
168.67 129 39.66 0.012* 
Acarbose 
combinations 
     
Glycomet + 
Glucobay  
Metformin+Acarbose 234.57 156.57 78.00 0.000*** 
Gemer + 
Glucobay 
Glimepride+ metformin 
+acarbose 
274 198.5 75.50  
0.000*** 
Glicizid + 
volix 
Glicizide+ Voligbose 236.17 171 65.16 0.001** 
Glycinorm + 
Glucobay 
Glicizide+ Acarbsoe 215 123 89.50 0.000*** 
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Brand name Generic name FBS 
before 
therapy 
FBS after 
therapy 
Mean FBS 
reduction 
(mg/dl) 
P value 
(before 
and after 
FBS) 
More than 
two 
combinations 
     
Gemer+ 
Gluconorm  
Glimepride+metformin+ 
Repaglinide 
184.8 145 39.87 0.000*** 
Glucobay + 
Glicizide + 
Janumet 
Acarbose +Glicizide 
+ Metformin+ 
sitagliptin 
351.33 215.33 136 0.003* 
Reclimet+ 
istamet   
Metformin +GLicizide+ 
sitaglipin 
175 127 49.00 0.000*** 
Janumet ( 
siatgliptin + 
metformin ) + 
Glcinorm 
Siatgliptin+ metformin+ 
Glicizide 
240 100 130.33 0.000*** 
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Table No 19: Average cost effective ratio of oral antidiabetic drugs. 
Drug(brand ) Generic name Cost per 
month 
Total cost Mean FBS 
reduction  
(mg/dl) 
ACER 
Monotherapy      
Glycomet Metformin 90 3693.38 42.03 87.85 
Glycinorm Glicizide 160.73 4167.63 22.26 187.16 
Gluconorm Repaglanide 168 2658.83 7.33 3625.76 
Amaryl Glimepride 365 3619.00 19.00 190.47 
Biguanides +  Sulphonyl ureas     
Gemer  Glimepride + metformin 328 3289.89 36.00 91.38 
Glycomet + 
Gemer  
Glimepride + metformin 372 3664 56.50 64.86 
Glycomet 
+Dianorm 
Glycomet + Glicizide 300 2010.50 18.30 109.86 
Glyciphage + 
semiglynase 
Metformin+ Glipizide 208 2966.00 19.60 151.32 
Glimisave + 
Glycomet 
Glimepride + 
Metformin 
210 1552.50 44.83 34.62 
Glycomet + 
Reclimet  
Metformin + glicizide 285 2238.33 36.66 61.04 
Glipizide + 
metformin 
Glipizide + metformin 1225 3085.55 17.55 175.81 
Glycomet 
+glimepride 
Metformin + glimepride 406 3135.63 47.90 65.44 
Glycomet + 
glycinorm 
Metformin +glicizide 270 2687.00 80.37 33.43 
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Drug(brand ) Generic name Cost per 
month 
Total cost Mean FBS 
reduction  
(mg/dl) 
ACER 
DPP4 
combinations 
     
Glycinorm + 
Galvus  
Glicizide + vidagliptin 780 3549 25.66 138.28 
Glimepride + 
sitagliptin 
Glimepride +sitagliptin 408 2457.00 12.60 195.00 
Glycinorm 
+galvusmet 
Glicizide + Vidagliptin 
+ Metformin 
825 4642.50 67.50 68.77 
Janumet Metformin +sitagliptin 758 4243.00 32.00 132.59 
Galvusmet Vidagliptin + 
Metformin 
372 3664.75 56.50 64.86 
Galvus  + 
Glycomet 
Vidagliptin+ 
Metformin 
1397 3265.33 39.66 82.32 
Acarbose 
combinations 
     
Glycomet + 
Glucobay  
Metformin+Acarbose 279 2910.71 78.00 37.31 
Gemer + 
Glucobay 
Glimepride+ metformin 
+acarbose 
936 3411.50 75.50 45.18 
Glicizid + 
volix 
Glicizide+ Voligbose 800 3903.33 65.16 59.89 
Glycinorm + 
Glucobay 
Glicizide+ Acarbsoe 342 2626.66 89.50 29.34 
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Drug(brand ) Generic name Cost per 
month 
Total cost Mean FBS 
reduction  
(mg/dl) 
ACER 
More than 
two 
combinations 
     
Gemer+ 
Gluconorm  
Glimepride+metformin+ 
Repaglinide 
356 2141.50 39.87 53.70 
Glucobay + 
Glicizide + 
Janumet 
Acarbose +Glicizide 
+ Metformin+ 
sitagliptin 
737 3627.00 136 26.66 
Reclimet+ 
istamet   
Metformin +GLicizide+ 
Sitaglipin 
892 3639.00 49.00 74.26 
Janumet + 
Glycinorm 
Siatgliptin+ metformin+ 
Glicizide 
1490 4679.50 130.33 35.90 
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Table No 20: Incremental cost effective ratio of oral antidiabetics 
Brand name Generic name Cost 
in one 
month 
Mean 
FBS 
reduction 
(Mg/dl) 
Increment
al cost 
Increme
ntal 
effect 
ICER 
Monotherap
y 
      
Glycomet Metformin 90 42.03 3693.38s 42.03 369.038 
Glycinorm Glicizide 160.73 22.26 4167.63 19.77 210.78 
Gluconorm Repaglanide 168 7.33 26588.83 34.70 766.13 
Amaryl Glimepride 365 19.00 3619.00 23.03 157.08 
Biguanides +  Sulphonyl ureas      
Gemer  Glimepride + 
metformin 
328 36.00 3289.99 6.03 544.83 
Glycomet + 
Gemer  
Glimepride + 
metformin 
372 56.50 3664.75 -14.46 -253.41 
Glycomet 
+Dianorm 
Glycomet + Glicizide 300 18.30 2010.50 23.75 84.65 
Glyciphage + 
semiglynase 
Metformin+ 
Glipizide 
208 19.60 2996.00 22.43 132.18 
Glimisave + 
Glycomet 
Glimepride + 
Metformin 
210 44.83 1552.50 -2.79 -555.49 
Glycomet + 
Reclimet  
Metformin + glicizide 285 36.66 2238.33 5.37 416.67 
Glipizide + 
metformin 
Glipizide + 
metformin 
1225 17.55 3085.55 24.48 126.00 
Glycomet 
+glimepride 
Metformin + 
glimepride 
406 47.90 3135.63 -5.87 -534.13 
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Glycomet + 
glycinorm 
Metformin +glicizide 270 80.37 2687.00 -38.33 -70.08 
DPP4 
combination 
      
Glycinorm + 
Galvus  
Glicizide + 
vidagliptin 
780 25.66 3549.33 16.37 216.79 
Glimepride + 
sitagliptin 
Glimepride 
+sitagliptin 
408 12.60 2457.00 29.43 83.46 
Glycinorm 
+galvusmet 
Glicizide + 
Vidagliptin + 
Metformin 
825 67.50 4642.50 -25.46 -182.33 
Janumet Metformin 
+sitagliptin 
758 32.00 4243.00 10.03 422.67 
Galvusmet Vidagliptin + 
Metformin 
215 15.00 2557.00 27.03 94.56 
Galvus  + 
Glycomet 
Vidagliptin+ 
Metformin 
1397 39.66 3265.33 2.37 1376.32 
Acarbose 
combination 
 
      
Glycomet + 
Glucobay  
Metformin+Acarbose 279 78.00 2910.71 -35.96 -80.93 
Gemer + 
Glucobay 
Glimepride+ 
metformin +acarbose 
936 75.50 3411.50 -33.46 -101.95 
Glicizid + 
volix 
Glicizide+ Voligbose 800 65.16 3903.333 -23.12 -168.77 
Glycinorm + 
Glucobay 
Glicizide+ Acarbose 342 89.50 2626.66 -47.46 -55.34 
More than 
two 
combination 
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Gemer+ 
Gluconorm  
Glimepride+metformi
n+Repaglinide 
356 39.87 2141.50 2.16 989.83 
Glucobay + 
Glicizide + 
Janumet 
Acarbose +Glicizide+ 
Metformin+ 
sitagliptin 
737 136.00 3627.00 -93.96 -38.60 
Reclimet+ 
istamet   
Metformin + 
GLicizide+ sitaglipin 
1446 48.80 4087.40 -6.96 -522.73 
Janumet + 
Glycinorm 
Siatgliptin+ 
metformin + 
Glicizide 
1490 130.33 4679.50 -88.29 -52.99 
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Table No 21: Cost effectiveness analysis of oral antidiabetic drugs. 
Brand Generic ACER ICER ACER/
ICER 
Quad
rant 
Typ
es 
Result 
Monother
apy 
       
Glycomet Metformin 87.85 369.03 0.238 I LC 
HE 
Dominant 
Glycinor
m 
Glicizide 187.16 210.78 0.887 I LC 
HE 
Dominant  
Gluconor
m 
Repaglanide 3625.7
6 
766.13 4.7315 I LC 
HE 
Dominant 
Amaryl Glimepride 190.47 157.08 1.212 I  LC 
HE 
Dominant  
Biguanid
es +  
Sulphonyl ureas       
Gemer  Glimepride + 
metformin 
91.38 544.83 0.1677 I LC 
HE 
Dominant  
Glycomet 
+ Gemer  
Glimepride + 
metformin 
64.86 -253.41 -0.2559 II HC 
HE 
Cost effective 
Glycomet 
+Dianorm 
Metformin+ Glicizide 109.86 84.65 1.297 I LC 
HE 
Dominant 
Glyciphag
e + 
semiglyna
se 
Metformin+ Glipizide 151.32 132.18 1.144 I LC 
HE 
Dominant 
Glimisave 
+ 
Glimepride + 
Metformin 
34.62 -555.49 -0.062 II HC Cost effective 
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Glycomet HE 
Glycomet 
+ 
Reclimet  
Metformin + glicizide 61.04 416.67 0.146 I LC 
HE 
Dominant 
Glipizide 
+ 
metformin 
Glipizide + metformin 175.81 126.00 1.395 I LC 
HE 
Dominant 
Glycomet 
+glimepri
de 
Metformin + 
glimepride 
65.44 -534.13 -0.122 II HC 
HE 
Cost effective 
Glycomet 
+ 
glycinorm 
Metformin +glicizide 33.43 -70.08 -0.477 II HC 
HE 
Cost effective 
DPP4 
combinati
on 
       
Glycinor
m + 
Galvus  
Glicizide + vidagliptin 138.28 216.79 0.636 I LC 
HE 
Dominant 
Glimeprid
e + 
sitagliptin 
Glimepride +sitagliptin 195.00 83.46 2.336 I LC 
HE 
Dominant 
Glycinor
m 
+galvusm
et 
Glicizide + Vidagliptin 
+ Metformin 
68.77 -182.33 -0.377 II HC 
HE 
Cost effective 
Janumet Metformin +sitagliptin 132.59 422.67 0.3136 I LC 
HE 
Dominant 
Galvusme
t 
Vidagliptin + 
Metformin 
64.86 94.56 0.685 I LC 
HE 
Dominant 
Galvus  + 
Glycomet 
Vidagliptin+ 
Metformin 
82.32 1376.3
2 
0.059 I LC 
HE 
Dominant 
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Acarbose 
combinati
on 
       
Glycomet 
+ 
Glucobay  
Metformin+Acarbose 37.31 -80.93 -0.4610 II HC 
HE 
Cost effective 
Gemer + 
Glucobay 
Glimepride+ metformin 
+acarbose 
45.18 -101.95 -0.443 II HC 
HE 
Cost effective 
Glicizid + 
volix 
Glicizide+ Voligbose 59.89 -168.77 -0.354 II HC 
HE 
Cost effective 
Glycinor
m + 
Glucobay 
Glicizide+ Acarbose 29.34 -55.34 -0.5302 II HC 
HE 
Cost effective 
More 
than two 
combinati
on 
       
Gemer+ 
Gluconor
m  
Glimepride+metformin
+Repaglinide 
53.70 989.83 0.054 I LC 
HE 
Dominant 
Glucobay 
+ 
Glicizide 
+ Janumet 
Acarbose +Glicizide+ 
Metformin+ sitagliptin 
26.66 -38.60 -0.6906 II HC 
HE 
Dominant 
Reclimet+ 
istamet   
Metformin + 
GLicizide+ sitaglipin 
74.26 -522.73 -0.142 II HC 
HE 
Cost effective 
1Janumet 
+ 
Glycinom 
Siatgliptin+ metformin 
+ Glicizide 
35.90 -52.99 -0.677 II HC 
HE 
Cost effective 
 
56 
 
Table No 22: Cost of Direct medical costs incurred by Type II Diabetes Mellitus patients on 
oral anitidiabetics 
No  Total oral 
antidiabetic 
charges 
incurred 
Total laboratory 
charges 
incurred 
Total physician 
charges 
incurred 
Total 
complication 
charges 
incurred 
210 patients 96457 207453 145850 136345 
Average for one 
patient for one 
month 
 
459.31 
 
987.87 
 
694.52 
 
649.26 
Total costs 
incurred by 210 
patients 
586105    
 
Figure No 17:  Cost of Direct medical costs incurred by Type II Diabetes Mellitus patients 
on oral anitidiabetics 
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Table No 23: Average cost incurred for direct medical cost of treating DM patients on oral 
antidiabetics for one month 
Parameter Cost in rupees Percentage 
Oral antidiabetic drug cost 459.931 16.47% 
Lab charges 987.87 35.38% 
Physician charges 694.52 24.88% 
Complication charges 649.26 23.25% 
Average total direct cost per patient 2791.581 100% 
 
 
Figure No 18: Average cost incurred for direct medical cost of treating DM patients on oral 
antidiabetics for one month 
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DISCUSSION 
 Research proposal approval was obtained from the Human Ethics committee of PSG 
Hospital. According to the study protocol, the number of patients to be studied was 303.  
However out of the data collected only 210 patients were fit for the inclusion criteria which 
included Type 2 Diabetic Mellitus patients who were on oral antidiabetics and had come for 
review atleast once during their therapy. It excluded patients who were lactating and pregnant or 
critically ill. 
 From the 210 patients evaluated the male were more in the study with 60% than the 
female (40%). This differed from most studies. It could be due to the variation of the population. 
Majority of patients were between the age of 60-70 years. Tri Murti et al had the same findings 
in a study done in Indonesia.
40
 Older adults are at high risk for the development of Type 2 
diabetes due to the combined effects of increasing insulin resistance and impaired pancreatic islet 
function with aging. Age-related insulin resistance appears to be primarily associated with 
adiposity, sarcopenia, and physical inactivity, which may partially explain the disproportionate 
success of the intensive lifestyle interventions.49 
 
Diabetes Mellitus is a progressive disease with many complications. This study 
highlighted on the common complications the diabetic patients have. Hypertension was the most 
common complication with 47% followed by diabetic foot ulcer15% and dyslipidemia 11.3%, 
ACS (9.5%), UTI (5.2%) and COPD(7.4%). Abdelaziz et al also had majority of the study 
patients having hypertension.
11 
Though it should be noted that hypertension may not always be a 
complication of DM. Some patients might have had HTN before DM diagnosis. However 
research heavily suggests that too much sugar may lead to hypertension. The excess sugars lead 
to weight gain which becomes a potential for high blood pressure. The high blood pressure 
propagates many complications e.g. ACS, hypertensive retinopathy, neuropathy. Therefore diab 
etic patients should make sure their blood pressure levels are within the charts. 
A study done by Sudha et al showed that biguanides were the most prescribed 
antidiabetic drugs.
41
 This was the case with this study which showed that biguanides were the 
mostly prescribed drugs both as a monotherapy and combination therapy. 28.2% patients 
received metformin monotherapy and most of the combination drugs had metfromin. This is due 
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to the effectiveness of metformin in blood sugar reduction and its benefit in reducing the CVD 
risk as well as the safety of the therapy. The least prescribed monotherapy was 
thiazolidinediones (TZD) (2.38%).  This could be due to the one too many side effects it has. 
Common side effects associated with TZDs include edema, weight gain, macular edema and 
heart failure. Moreover, they may cause hypoglycemia when combined with other antidiabetic 
drugs as well as decrease hematocrit and hemoglobin levels. Increased bone fracture risk is 
another TZD-related side effect.  
Combination of sulphonyl ureas and biguanides were the most used combinations in this 
study. Table No 10 and figure No 7 show 28% prevalence of the same. Akshay et al concluded in 
their study that biguanide and sulphonyl ureas were the most prescribed combinations. This 
could be because of the different mechanism of action and the synergistic effect both drugs have 
on each other. Biguanides lowers blood sugar by decreasing the making muscle tissue more 
sensitive to insulin so that glucose can be absorbed. Sulphonyl ureas stimulate the beta cells of 
the pancreas to secrete more insulin.
40 
The least common combination was that of biguanides and the DPP4 inhibitors. (1.45%) 
DPP4 inhibitors are initiated as a 3rd line agent in patients with higher post prandial glucose as 
they effectively reduce it. The most commonly prescribed anti diabetic agents along with 
Gliptins is Metformin, followed by Sulphonyl ureas, as a combination pill, use of Metformin and 
Sitagliptin is common.
42
Sitagliptin and metformin provide additive glycemic improvements, 
suggesting a synergy between the agents. However, although sitagliptin is effective, its cost and 
limited long-term data may restrict its use.
50 
Other combinations seen in this study were 
sulphonyl ureas and DPP4 inhibitors( 10.38%), and Alpha glucosidase inhibitors with biguanides 
and sulphonyl ureas (10.95%)
 
Adding a second drug is usually better than increasing the dosage of an agent that has 
already been given in a nearly maximum dosage. In some patients three drugs.
43 
Three 
combination antidiabetic drug was utilized up to 10.74% of the total prescriptions. This is 
because three drugs therapy give a better control of blood sugar. A study has shown that three 
drug therapy is not common practice. However, three oral agents (e.g. metformin, 
sulfonylurea, pioglitazone) can be considered in patients with A1C values that are not too far 
from goal (A1C ≤8.5 percent).52 
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The cost of the antidiabetic therapy was calculated over a period of one month. These 
charges of the different therapies were reached upon by getting the average of the costs of the 
different prescribed brands. In the monotherapy the average cost of metformin was found to be 
the cheapest at Rs 90 per month and Glimepride was the most expensive monotherapy at an 
average cost of Rs 189 as seen in Table 13and Figure 12. Study conducted at John Hopkins 
University Research concluded that Metformin is the safest and cheapest oral antidiabetic drug.
44 
Repaglanide had average cost of Rs 168 per month and Glicizide had an average cost of Rs 160 
per month. 
In the combination of sulphonyl ureas and biguanides, Glimepride and Metformin 
combinations were more expensive (Rs 335) than that of Glicizide and Metformin (Rs 254.4) in 
Table No 14 and Figure 13. DPP4 combinations with metformin were less expensive at Rs 397.4 
than that of DPP4 and sulphonyl ureas (Rs 671) This could be due to the fact that biguanides are 
much cheaper than sulphonyl ureas. The acarbose combinations were cheaper with metformin 
(Rs 279) than with sulphonyl ureas (Rs 342) as seen in Table 16 and Figure 15.  
This study considered the effectiveness of the oral antidiabetics by taking FBS as the unit 
of observation in the diabetic patients. This is because all patients had their FBS values evaluated 
and reviewed after a month unlike the other units of reduction. Table 17 and Figure 16 shows the 
laboratory investigations the patients underwent. Majority of patients had both the FBS and 
PPBS evaluated. Singh et al conducted a study on pharmacoeconomic and drug utilization of 
antidiabetic drugs and used Fasting Blood Sugar to evaluate the effectiveness of the 
antidiabetics. 
28
The ADA has recognized the fasting plasma glucose (FPG), as the diagnostic test 
of choice. PPBS values can change due to many variables, such as physical activity, insulin 
sensitivity, gastric emptying rate, and meal composition .HbA1c is not recommended as a 
diagnostic or a screening test because it is considered that HbA1c is inferior to FPG or post-load 
glucose values at predicting type 2 diabetes because the existence of hemoglobin or red cell 
abnormalities can increase the variability of HbA1c values.
51 
Table No 18 show the calculated effectiveness of the given oral antidiabetic drugs using 
the p value. In the monotherapy, Metformin was the most effective drug with a p value of 0.001 
and an average FBS reduction of 42 mg/dl as compared to the sulphonyl ureas and 
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thiazolidinediones which had a p value of 0.228 and 0.303 respectively and an average FBS 
reduction of 19 and 7 mg/dl respectively from the baseline value. 
 In combination drugs the Biguanides and sulphonyl ureas show significant effectiveness 
with the combinations of Glimepride and metformin in different brand names with a p value of 
0.000.The acarbose and metformin combinations have more effectivenesss (p value=0.000)than 
acarbose and sulphonyl ureas(p value =0.001). The two combination drugs have more 
effectiveness than monotherapy. And the more than two drugs have the most effectiveness when 
compared to the single and two combination therapy. Most three drugs combinations have a p 
value of 0.000.This is a proven fact on a study done by Rajeshwari et al.
43 
The three drug therapy 
containing Metformin, Glicizide and Sitagliptin had the most effectiveness . Also the 
combination of Metformin, Glimepride and Repaglanide. 
To determine the cost effective therapy the ACER and ICER were calculated as shown in 
Table 19 and 20. In an ICER quadrant one of the four responses are available: Quadrant 1 is 
dominant which has low cost and high effect drugs. Quadrant II is Cost Effective with High cost 
and high Effect. Quadrant III is the Excluded category has drugs with high cost and low effect. 
Quadrant IV has Questionable drugs which have the low cost and low effect.  Monotherapies 
were all found in the Quadrant I which suggests they are all of low cost and high effect. The cost 
effective therapies in Quadrant II had high cost and high effect and were found to be Glimepride 
and metformin and the acarbose combinations ie. Acarbose and Metformin and Acarbose and 
Glicizide as well as the three drug combinations. A study done by Abdelaziz et al also reported 
that Glimepride and metformin were the most cost effective combination therapy.
11 
Study done 
in Chinese patients supported the use of Acarbose in combination with Metformin and found out 
that Acarbose is as safe and effective as Metformin, Vidagliptin and Glimepride and also has 
benefits on reducing the CVD risk.
48 
This study also undertook to calculate the cost of illness incurred by the ambulatory 
diabetic patients who were taking oral antidiabetics. The total medical cost incurred for the 210 
patients over a period of one month was 5.86 lakhs and was arrived at by calculating the total 
costs of drugs, laboratory charges, physician charges and complications charges. The average 
total medical cost incurred by a single ambulatory patient was Rs 2791.58.  The laboratory 
charges took the largest part of the cost incurred by patients (35.38%) This could be explained by 
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the fact that majority of diabetic patients have complications and these complications are 
reviewed by several laboratory values. The physician charges were the second highest charges 
incurred at 24.88%. This may be explained by frequent visits patients make due to complication 
of disease. The complication charges come in third with 23.25% of total cost. DM direct 
treatment cost increases with presence and progression of DM related complications. 
16
 The oral 
antidiabetics were the least incurred costs with 16.47% of total costs. 
 This finding varies from other studies which had the average cost incurred by one patient 
to be   Rs 7386. 
11 
This variation could be due to the fact that the study considered the costs of 
hospitalization and nurses where as this study only included the direct medical cost incurred by 
ambulatory patients thus the hospitalization and nurses charges were not included. 
Indirect costs were not included in this study but it is important to note that these are also 
costs that the diabetic patients incur. The indirect costs typically consist of work loss, worker 
replacement, and reduced productivity from illness and disease. Due to disease patients end up 
having lost work days which account for the indirect costs. 
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CONCLUSION 
 Diabetes Mellitus is a chronic and progressive disorder which affects patients for a life 
time and this is why it should be a burden to the medical faculty to come up with effective yet 
affordable means of treating this growing pandemic. Effective means because diabetes is a 
progressive disease with a series of complications that come if the blood sugar is poorly 
controlled. Affordable means to treat the disease because this is a disease a patient has to deal 
with for a lifetime once diagnosed. Hence this becomes a need and not a want that the patients 
have to fulfill. Making drugs affordable for patients to be able to easily access regardless of 
economic status should be a priority for the medical team. 
 The study concluded that the male patients were more than the female patients and that 
most of the Type II Diabetes Mellitus were between the age of 60-70 years. Hypertension was 
the major complication the diabetic patients had in this study followed closely by diabetic foot 
ulcer. 
 This study has sought to come up with the most effective yet affordable oral antidiabetic 
drugs. The combination therapy was more prescribed than the monotherapy in this study. The 
study has concluded that the combination of Glimepride and metformin is a cost effective 
therapy. 
The acarbose combinations were also cost effective according to this study. However the 
acarbose combinations are rarely used. Studies have supported the effective use of acarbose in 
clinical practice because of their safety and benefits such as reducing the risk of CVD and do not 
cause weight gain. Therefore acarbose and its combinations should be considered for therapy 
which is not a common practice as of now. 
 Three drug combinations also have been seen to be cost effective in this study. Instead of 
going to insulin therapy the three oral drug therapy should be utilized unless the blood sugar is 
not controlled by oral antidiabetics. However if patient is controlling blood sugar efficiently with 
3 oral hypoglycemic agents this should be maintained and constant monitoring to be done. 
  This study found out that the cost of illness incurred in one month by an 
individual patient was averagely Rs 2781.58. This is a huge amount considering it only involves 
64 
 
the medical costs ambulatory patients paid. Hence treating diabetes is quite expensive. However 
to efficiently establish the economic burden to the patients, the patients income has to be known. 
Thus efforts to reduce this burden of the disease should be employed. This should include 
actively talking about the disease and encouraging healthy eating habits and living.  Physicians 
should employ cost effective therapy options and the pharmacists should take on their role 
seriously in patient education in both rural and urban areas. Patients should be taught on 
importance of being compliant to drugs to keep the blood sugar level controlled. Finally the 
government of India should help in health insurance to help share the economic burden with the 
patients. 
 Clinical pharmacists have a role to play in the effort to lower the economic burden of the 
disease. By making this disease aware to the society to avoid more people being affected and 
also educating the patients on the disease knowledge and the importance of patient compliance to 
help prevent the progression of the disease. Clinical pharmacists also have a role to play in 
advising the physicians on the cost effective therapies available. 
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LIMITATIONS OF THE STUDY 
 The study did not include indirect costs incurred by the diabetic patients whereas this 
is a cost that diabetic patients have to incur due to loss of work days, loss of 
productivity because of the disease manifestations. 
 For cost effective analysis more number of patients have to be used to calculate 
effective cost effectiveness. 
 A prospective study would have provided more data especially on the indirect costs 
incurred by the patients.  
 Lack of adequately being able to know the patients income to come up with efficient 
economic burden on a particular patient. 
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